Dravet syndrome

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Graduate School of Asia-Pacific Studies, G&A, Central nervous system, Private Securities Litigation Reform Act, Research, GPCR, Investment, Seizure, Longboard, Dravet syndrome, Government, Coronavirus, FDA, Lennox–Gastaut syndrome, Judgement, COVID-19, CB2, Marketing, CNS, U.S. Securities and Exchange Commission, Disagreement, Clinical trial, Medication, Dees, Acquisition, R, Security (finance), G protein-coupled receptor, SEC, CDKL5, Pharmaceutical industry, Cryptocurrency, Pfizer

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022.
  • LP659, an oral, selective, centrally acting S1P receptor modulator, for which we have a pre-IND meeting scheduled with the FDA in the fourth quarter of 2022.
  • Third Quarter 2022 Financial Results:
    At September 30, 2022, Longboards cash, cash equivalents and short-term investments were approximately $77.3 million.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Cannabis Drugs Market Size to Surpass US$ 2013.42 Billion by 2030 | Exclusive Report by Growth Plus Reports

Retrieved on: 
Thursday, October 6, 2022
Physician, Dronabinol, Cannabis, Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Multiple sclerosis, Lennox–Gastaut syndrome, CAGR, U.S. FDA, Alzheimer's disease, Seizure, Epilepsy, Vomiting, US, Dravet syndrome, COVID-19, Pharmaceutical industry, Medicinal plants, Drug, Cannabidiol, Nabilone, Fibromyalgia, Application

The increased cannabis approvals by regulatory bodies for medicinal use, rising availability of cannabis drugs in online pharmacy, and more and more physicians prescribing cannabis for medical and recreational purposes is driving the global cannabis drugs market.

Key Points: 
  • The increased cannabis approvals by regulatory bodies for medicinal use, rising availability of cannabis drugs in online pharmacy, and more and more physicians prescribing cannabis for medical and recreational purposes is driving the global cannabis drugs market.
  • The global cannabis drugs market has been analyzed from three different perspectives brand, application, and region.
  • Download PDF Brochure of Cannabis Drugs Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://growthplusreports.com/inquiry/request-sample/cannabis-drugs-mark...
    The global cannabis drugs market has been divided into four approved brands namely:
    The largest revenue share was accounted for by the Epidiolex brand segment, which dominated the market for cannabis medications and is predicted to increase at the fastest rate over the forecasted period.
  • The prominent players operating in the global cannabis drugs market:

Cannabis Drugs Market Size to Surpass US$ 2013.42 Billion by 2030 | Exclusive Report by Growth Plus Reports

Retrieved on: 
Thursday, October 6, 2022
Physician, Dronabinol, Cannabis, Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Multiple sclerosis, Lennox–Gastaut syndrome, CAGR, U.S. FDA, Alzheimer's disease, Seizure, Epilepsy, Vomiting, US, Dravet syndrome, COVID-19, Pharmaceutical industry, Medicinal plants, Drug, Cannabidiol, Nabilone, Fibromyalgia, Application

The increased cannabis approvals by regulatory bodies for medicinal use, rising availability of cannabis drugs in online pharmacy, and more and more physicians prescribing cannabis for medical and recreational purposes is driving the global cannabis drugs market.

Key Points: 
  • The increased cannabis approvals by regulatory bodies for medicinal use, rising availability of cannabis drugs in online pharmacy, and more and more physicians prescribing cannabis for medical and recreational purposes is driving the global cannabis drugs market.
  • The global cannabis drugs market has been analyzed from three different perspectives brand, application, and region.
  • Download PDF Brochure of Cannabis Drugs Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://growthplusreports.com/inquiry/request-sample/cannabis-drugs-mark...
    The global cannabis drugs market has been divided into four approved brands namely:
    The largest revenue share was accounted for by the Epidiolex brand segment, which dominated the market for cannabis medications and is predicted to increase at the fastest rate over the forecasted period.
  • The prominent players operating in the global cannabis drugs market:

ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer

Retrieved on: 
Tuesday, September 13, 2022
Neuroscience, AD, Chicago (franchise), U.S. Securities and Exchange Commission, Leadership, Drug development, Amyotrophic lateral sclerosis, ALS, Risk, PROMIS, Multiple system atrophy, Entrepreneurship, MSA, Company, Acquisition, NDA, IPO, Food and Drug Administration, LGS, Toronto Stock Exchange, EMA, Dravet syndrome, FDA, Lennox–Gastaut syndrome, IND, News, Partnership, Lists of diseases, Strategic planning, CEO, Novartis, Board of directors, Epitope, Board, Security (finance), GLOBE, Amyloid, GlaxoSmithKline, PMN, Therapy, Doctor of Philosophy, TSX, Neurodegeneration, MAA, European Medicines Agency, University, Disease, Pharmaceutical industry, Nasdaq, Dravet Syndrome Foundation, Pfizer

The past 18 months have been transformative for ProMIS, stated Eugene Williams, ProMIS Chairman and Co-Founder.

Key Points: 
  • The past 18 months have been transformative for ProMIS, stated Eugene Williams, ProMIS Chairman and Co-Founder.
  • We have also continued to expand our strong management team, having added to the team earlier this year Dr. Larry Altstiel as Chief Medical Officer and, in late 2021, Gavin Malenfant as Chief Operating Officer.
  • Gail has a distinguished track record of accomplishments in both large pharma and biotech, and she has invaluable expertise in neurologic disease drug development.
  • I am honored and excited to take on the role of CEO at ProMIS, remarked Gail Farfel.

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Wednesday, September 7, 2022
Security (finance), COVID-19, Technology, Therapy, NASDAQ, Seizure, Lennox–Gastaut syndrome, Epilepsy, GABA, SEC, Forward-looking statement, U.S. Securities and Exchange Commission, Lists of diseases, GLOBE, Conference, Takeda, Dravet syndrome, Webcast, Risk, KCC2, Event, Pharmaceutical industry

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science.

Key Points: 
  • Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science.
  • Ovids pipeline of small molecule and genetic medicines candidates seek to meaningfully improve the lives of people and families affected by epilepsies.
  • Ovid is developing OV329, a GABA aminotransferase inhibitor, for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies.
  • In addition, Ovid maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally.

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Retrieved on: 
Wednesday, August 31, 2022
Nicotine, DS, Fever, CEO, CSE, Safety, Pain, Lists of diseases, Pharmacokinetics, Seizure, Cannabidiol, Central nervous system, Impulsivity, Disorder, Psilocybin, Epilepsy, Legislation, Brain, Achievement, PTSD, SCN1A, NCT, Status epilepticus, Ingestive behaviors, Depression, GLOBE, Pharmacology, Company, FDA, Bright Minds In Action Learning Village, Population, News, Fenfluramine, Drug development, Patient, 2-Methyl-5-hydroxytryptamine, Pharmaceutical industry, Risk management, Dravet syndrome, Serotonin

The Phase I trial is being conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial center specializing in a range of early-phase trials and first-time in-human studies.

Key Points: 
  • The Phase I trial is being conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial center specializing in a range of early-phase trials and first-time in-human studies.
  • The trial aims to evaluate the safety, tolerability and other pharmacokinetics of BMB-101 for use in Phase II clinical trials.
  • Dosing the initial subject in the first-in-human trial of BMB-101 is an exciting milestone for Bright Minds.
  • Forward looking information in this news release contains information related to the Phase I clinical trial and the future therapeutic potential of BMB-101.

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

Retrieved on: 
Thursday, August 25, 2022
Health, Biotechnology, Security (finance), ADOA, COVID-19, Asos, Central nervous system, Therapy, Severe cognitive impairment, Founder effect, Disease, Tissue, Incidence, Diagnosis, TANGO, Oregon Health & Science University School of Dentistry, U.S. Securities and Exchange Commission, Targeted molecular therapy for neuroblastoma, Stoke, Medicine, Patient, Neurology, Nasdaq, FDA, FALCON, Twitter, Oregon Health Plan, Dravet syndrome, Mutation, Haploinsufficiency, Risk, Annual report, OPA1, Private Securities Litigation Reform Act, Eye, ASO, Life, Pharmaceutical industry, Vaccine, Ophthalmology

FALCON is a two-year prospective natural history study in patients who have a confirmed diagnosis of ADOA that is caused by an OPA1 mutation.

Key Points: 
  • FALCON is a two-year prospective natural history study in patients who have a confirmed diagnosis of ADOA that is caused by an OPA1 mutation.
  • Autosomal dominant optic atrophy (ADOA) is the most common inherited optic nerve disorder.
  • STK-002 is a proprietary antisense oligonucleotide (ASO) in preclinical development for the treatment of Autosomal Dominant Optic Atrophy (ADOA).
  • Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder.

Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Tuesday, August 9, 2022
U.S. Securities and Exchange Commission, Neuroscience Research Australia, Risk, Trial of the century, GLOBE, MB, NEW, Forward-looking statement, Technology, SEC, Therapeutic index, COVID, IND, Epilepsy, Security (finance), Dravet syndrome, Research, KCC2, Therapy, COVID-19, Company, Fragile X syndrome, Lists of diseases, Angelman syndrome, Partnership, NASDAQ, Seizure, Lennox–Gastaut syndrome, GABA, Drug discovery, Efficiency, Investigational New Drug, Pharmaceutical industry, Video game, Takeda

Ovid presented preclinical data that will support the IND submission for OV329 in the second half 2022.

Key Points: 
  • Ovid presented preclinical data that will support the IND submission for OV329 in the second half 2022.
  • Ovid plans to submit an IND and initiate a Phase 1 trial in the second half 2022.
  • General and administrative expenses were $8.3 million for the quarter ended June30, 2022, compared to $6.6 million for the same period in 2021.
  • Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science.

Dravet Syndrome Treatment Market Report 2022-2029: Stiripentol and Cannabidiol to Contribute to Significant Growth of 11.7% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 9, 2022
Health, Pharmaceutical, FDA, Dravet syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lists of diseases, DST, Food, GW Pharmaceuticals, Stiripentol, Chapter Four, Chapter Five, Chapter Three, USFDA, Safety, Awareness, Geography, CAGR, Research, Ho Chi Minh City Metro (Earlier proposals), Seizure, Chapter Six, Type, Efficiency, Pharmaceutical industry, Fertilizer, Cannabidiol, Cannabidiol

The "Dravet Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dravet Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029" report has been added to ResearchAndMarkets.com's offering.
  • However, recent drug approvals for Dravet syndrome treatment has increased the overall market size and attracted attention of major pharmaceutical companies.
  • Thus, overall environment of Dravet syndrome treatment market is growing significantly due to strong drug pipeline and recently approved drugs.
  • Global Dravet Syndrome Treatment (DST) Market: Market Dynamics and Future Outlook
    Chapter 4.

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Retrieved on: 
Monday, August 8, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, FDA, Dravet syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Movement, Death, Government budget balance, CSF, Asos, SUDEP, ASO, Retinal ganglion cell, Risk, IVT, Diagnosis, Technology, NHP, Cognition, Targeted molecular therapy for neuroblastoma, FALCON, Sleep, Haploinsufficiency, Research, Caregiver, Cerebrospinal fluid, TANGO, Language, Plasma, Patient, Quality of life, Therapy, Company, Contract, Prognosis, License, Seizure, RGC, Autonomic nervous system, Intellectual disability, RNA, Safety, Lists of diseases, Epilepsy, Collaboration, OLE, ADOA, Protein, Nasdaq, SCN1A, Food, EMA, Pharmacokinetics, Disease, Vaccine, Pharmaceutical industry, Cryptocurrency, Online gambling, Animal, Stoke, OPA1

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the second quarter of 2022 and provided business updates.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the second quarter of 2022 and provided business updates.
  • In the second half of 2022, the Company expects to begin enrollment in a prospective natural history study (FALCON) of people living with ADOA.
  • Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.
  • Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder.